Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, pr... Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.1 | -25.2707581227 | 8.31 | 8.6099 | 6.21 | 41943 | 7.40658991 | CS |
4 | -0.58 | -8.54197349043 | 6.79 | 8.6099 | 5.44 | 54896 | 6.89134476 | CS |
12 | 1.61 | 35 | 4.6 | 19.44 | 4.06 | 624739 | 11.92804302 | CS |
26 | -2.665 | -30.0281690141 | 8.875 | 19.44 | 4.06 | 302540 | 11.47643368 | CS |
52 | -18.54 | -74.9090909091 | 24.75 | 24.75 | 4.06 | 217326 | 12.13517008 | CS |
156 | -18.54 | -74.9090909091 | 24.75 | 24.75 | 4.06 | 217326 | 12.13517008 | CS |
260 | -18.54 | -74.9090909091 | 24.75 | 24.75 | 4.06 | 217326 | 12.13517008 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions